title: MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer.
authors.affiliation: Tufts University School of Medicine. Boston, MA, USA. wsaif@tuftsmedicalcenter.org.
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D006801:Humans; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D000093542:Gemcitabine; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D013395:Sucrose / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002166:Camptothecin; D003841:Deoxycytidine; D004338:Drug Combinations; D000093542:Gemcitabine; C584112:irinotecan sucrosofate; D013395:Sucrose